Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for IDL Diagnostics AB's FCF Yield % or its related term are showing as below:
OSTO:IDLDX'
s FCF Yield % Range Over the Past 10 Years
Min: -79.89 Med: -12.34 Max: 1.52
Current: -6.05
During the past 13 years, the highest FCF Yield % of IDL Diagnostics AB was 1.52%. The lowest was -79.89%. And the median was -12.34%.
OSTO:IDLDX's FCF Yield % is ranked worse than 62.91% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.23
vs OSTO:IDLDX: -6.05
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
IDL Diagnostics AB FCF Yield % Related Terms
IDL Diagnostics AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IDLDX vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (OSTO:IDLDX) has a FCF Yield % of -6.05 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on IDL Diagnostics AB and its competitors. According to the industry distribution chart, IDL Diagnostics AB ranks #134 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 62.9%.
Is IDL Diagnostics AB's FCF Yield % too high?
IDL Diagnostics AB's current FCF Yield % is -6.05. Based on the distribution chart, IDL Diagnostics AB ranks #134 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #134 out of 213 companies for FCF Yield %. This places IDL Diagnostics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on IDL Diagnostics AB and its competitors. IDL Diagnostics AB's current FCF Yield % is -6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.42 — trading 21.9% below its estimated fair value. The current FCF Yield % is -6.05. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current FCF Yield % is -6.05 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of kr0.42 is trading 21.9% below its estimated GF Value™ of kr0.54.
GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.
Key valuation signals for OSTO:IDLDX:
FCF Yield %: -6.05
GF Value™: kr0.54 vs. price of kr0.42 (21.9% below fair value)
No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for OSTO:IDLDX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDLDX has been successfully added to your 
